搜尋結果
2024年4月5日 · MERISLON TAB 6MG Registration No.: HK-48603 Certificate Holder: EISAI (HONG KONG) CO LTD Certificate Holder Address:
2024年3月29日 · 它是一種常見的內耳疾病，會立即造成眩暈的狀況，有點類似快速轉幾圈後，突然停下來，感覺房間還在轉、然後失去平衡的經驗。. 除了天旋地轉，還會伴隨耳鳴、時而聽不到，有時候還會覺得耳內充滿壓力、有悶塞感。. 大多數的梅尼爾氏症病人只一耳有問題 ...
2024年3月22日 · There is news related to local recall of this product within six months. For more details, please click the red flag of the product. The product is conditionally approved with very limited safety, efficacy, and quality data for public ...
2024年4月2日 · 甲磺酸倍他司汀: 一种组胺受体家族拮抗剂药物，由Eisai Co., Ltd. (卫材株式会社)公司最早进行研发，目前全球最高研发状态为批准上市，作用机制: 组胺受体家族拮抗剂，治疗领域: 神经系统疾病,耳鼻咽喉疾病，在研适应症: 梅尼埃病,眩晕，在研机构: Eisai Co., Ltd.。
2024年3月29日 · March 29, 2024. Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon ® (generic name: betahistine mesilate) and muscle relaxant Myonal ® (generic name: eperisone hydrochloride) in ...
6 天前 · Eisai said Friday that it agreed to sell Japanese rights for the vertigo treatment Merislon (betahistine mesilate) and the antispasmodic drug Myonal (eperisone hydrochloride) to Kaken Pharmaceutical.The drugs have long been used by patients in Japan since their
2024年4月2日 · Eisai said Friday that it agreed to sell Japanese rights for the vertigo treatment Merislon (betahistine mesilate) and the antispasmodic drug Myonal (eperisone hydrochloride) to Kaken Pharmaceutical.The drugs have long been used by patients in Japan since their
